The Central Drugs Standard Control Organization, the U.S. FDA's counterpart in India, hopes to better regulate the pharma sector with a tenfold increase of its drug inspection staff. The agency also intends to bolster state-level regulatory bodies and create eight additional central research facilities to address the rising number of clinical studies in the country.

Related Summaries